Medicines Australia announces appointment of new Board Chair 

The Board of Medicines Australia is pleased to announce the appointment of Ms Sue MacLeman as the new Chair of Medicines Australia. 

Ms MacLeman has more than 30 years’ experience as a pharmaceutical, biotechnology and medical technology executive having held senior roles across Australia’s corporate and life sciences sector.  

As an experienced corporate leader and Board Director, Ms MacLeman has served as CEO and Board member of several ASX, AIM and NASDAQ-listed companies in the healthtech sector. She is a Non-Executive Director on public, private and not-for-profit boards and is appointed to several academic, industry and government advisory boards and committees.  

“I am honoured to be appointed as Chair of Medicines Australia and I look forward to working with the Medicines Australia Board and Executive to continue championing the latest advancements in medicine, and advocating for patients to have fast, universal access to new treatments,” Ms MacLeman said. 

Ms MacLeman’s broad commercial and technical experience is underpinned by a Bachelor of Pharmacy from the University of Queensland, a Master of Laws from Deakin University and a Master of Marketing from Melbourne Business School. 

She is also a member of the NSW Government Innovation and Productivity Council, Fellow and a Non-Executive Director of the Australian Academy of Technology and Engineering and Fellow/Graduate of Australian Institute of Company Directors. 

In welcoming Ms MacLeman, Medicines Australia CEO Liz de Somer said, “I congratulate Ms MacLeman on her appointment on behalf of the Board and our members. We are looking forward to her decades of experience, knowledge and leadership being applied to advocating for a stronger Pharmaceutical Benefits Scheme with faster patient access to medicines, and to strengthening Australia’s life sciences sector.  

“With the need to get moving with Health Technology Assessment reform, the ongoing work to implement our Strategic Agreement with the Government, and our work to ensure Australia’s competitiveness as a destination for clinical trials remains, we look forward to Ms MacLeman’s stewardship at this crucial time for our industry,” she adds. 

____________________________________________________________________ 
 

Media enquiries to:  Anne-Marie Sparrow, Medicines Australia /Cube – media@medicinesaustralia.com.au  or 0417 421 560